Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety
Annals of Clinical and Experimental Neurology · 2024
DOI: 10.17816/acen.1027 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Clinical and Experimental Neurology, 2024. Verfasst von Nobel Budiputra und 2 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Monoclonal antibodies (mAb) emerged as a possible option in addressing the partial response to current treatment modalities in chronic low back pain (CLBP). Objective: to evaluate the efficacy and safety of mAb for CLBP. Materials and Methods. Randomized controlled trials on adult patients with CLBP who received mAb-therapy compared to those who did not as a control group. The result was the changes in Low Back Pain Intensity (LBPI) Numeric Rating Score and Roland–Morris Disability Questionnaire (RMDQ) indicating improved pain, disability, and the risk of adverse events. Meta-analysis, risk of bias, and confidence in the evidence for each analysis were assessed. We aimed at reviewing current treatment methods for degenerative lumbosacral spinal stenosis with an emphasis on surgical treatment methods.
Results
Six studies were included, with a total of 3851 participants. mAb significantly reduce LBPI and RMDQ score (weighted mean difference –1.48; 95% CI –2.63 to –0.33; p = 0.01). Tanezumab and fasinumab were significantly reduced both LBPI (weighted mean difference of –4.11; 95% CI –6.27 to –1.95; p = 0.0002 and weighted mean difference –0.24; 95% CI –0.47 to –0.02; p = 0.04 respectively) and RMDQ scores (weighted mean difference –3.72; 95% –5.48 to –1.97 and weighted mean difference –0.50; 95% –0.73 to –0.26 respectively, both p 0.0001). The mAb have significantly greater odds of any adverse events (OR 1.23; 95% 1.06 to 1.43; p = 0.007) but no greater odds regarding serious adverse events (OR 1.00; 95% 0.69 to 1.46; p = 0.98).
Conclusion
Depending on the types of drugs used, mAb had a favorable outcome and were relatively safe in reducing LBPI and RMDQ scores.
Zitieren
APA
Budiputra, N., Budiputri, C. L., & Muljono, M. P. (2024). Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety. Annals of Clinical and Experimental Neurology. https://doi.org/10.17816/acen.1027
Vancouver
Budiputra N, Budiputri CL, Muljono MP. Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety. Annals of Clinical and Experimental Neurology. 2024. doi:10.17816/acen.1027
BibTeX
@article{Budiputra2024,
author = {Budiputra, Nobel and Budiputri, Charista Lydia and Muljono, Michelle Patricia},
title = {Monoclonal antibodies as analgesia of chronic low back pain: a systematic review and meta-analysis of efficacy and safety},
journal = {Annals of Clinical and Experimental Neurology},
year = {2024},
doi = {10.17816/acen.1027}
}
EUVIMED